Kanis, J.A. http://orcid.org/0000-0002-3129-4326
Johansson, H.
McCloskey, E.V.
Liu, E.
Åkesson, K.E.
Anderson, F.A.
Azagra, R.
Bager, C.L.
Beaudart, C.
Bischoff-Ferrari, H.A.
Biver, E.
Bruyère, O.
Cauley, J.A.
Center, J.R.
Chapurlat, R.
Christiansen, C.
Cooper, C.
Crandall, C.J.
Cummings, S.R.
da Silva, J.A.P.
Dawson-Hughes, B.
Diez-Perez, A.
Dufour, A.B.
Eisman, J.A.
Elders, P.J.M.
Ferrari, S.
Fujita, Y.
Fujiwara, S.
Glüer, C.-C.
Goldshtein, I.
Goltzman, D.
Gudnason, V.
Hall, J.
Hans, D.
Hoff, M.
Hollick, R.J.
Huisman, M.
Iki, M.
Ish-Shalom, S.
Jones, G.
Karlsson, M.K.
Khosla, S.
Kiel, D.P.
Koh, W.-P.
Koromani, F.
Kotowicz, M.A.
Kröger, H.
Kwok, T.
Lamy, O.
Langhammer, A.
Larijani, B.
Lippuner, K.
Mellström, D.
Merlijn, T.
Nordström, A.
Nordström, P.
O’Neill, T.W.
Obermayer-Pietsch, B.
Ohlsson, C.
Orwoll, E.S.
Pasco, J.A.
Rivadeneira, F.
Schott, A.-M.
Shiroma, E.J.
Siggeirsdottir, K.
Simonsick, E.M.
Sornay-Rendu, E.
Sund, R.
Swart, K.M.A.
Szulc, P.
Tamaki, J.
Torgerson, D.J.
van Schoor, N.M.
van Staa, T.P.
Vila, J.
Wareham, N.J.
Wright, N.C.
Yoshimura, N.
Zillikens, M.C.
Zwart, M.
Vandenput, L.
Harvey, N.C.
Lorentzon, M.
Leslie, W.D.
Article History
Received: 22 March 2023
Accepted: 22 July 2023
First Online: 11 August 2023
Declarations
:
: All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield. Participant data will be stored in coded, de-identified form. Only summary statistics and aggregate data will be published, not allowing for identification of individual study participants.
: All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield.
: J.A. Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases. E.V. McCloskey, W.D. Leslie, M. Lorentzon, N.C. Harvey, E. Liu, L. Vandenput, and H. Johansson are members of the FRAX team. J.A. Kanis, N.C. Harvey, and E.V. McCloskey are members of the advisory body to the National Osteoporosis Guideline Group. J.A. Kanis reports no additional competing interests. K.E. Åkesson has no financial interest related to FRAX; chaired the National SALAR Group for Person-Centered Care Pathway Osteoporosis. F.A. Anderson led the team that developed GLOW, while director of the Center for Outcomes Research at the University of Massachusetts Medical School; he has no financial interest in FRAX. R. Azagra has received funding for research from Instituto Carlos III of Spanish Ministry of Health, IDIAP Jordi Gol of Catalan Government, and from Scientific Societies SEMFYC and SEIOMM. C.L. Bager is employed at Nordic Bioscience and owns stock in Nordic Bioscience. She declares no competing interests in relation to this work. H.A. Bischoff-Ferrari has no financial interest in FRAX. For the DO-HEALTH trial cohort, Prof. Bischoff-Ferrari reports independent and investigator-initiated grants from European Commission Framework 7 Research Program, from the University of Zurich, from NESTEC, from Pfizer Consumer Healthcare, from Streuli Pharma, plus non-financial support from DNP. For the study cohort extension, she reports independent and investigator-initiated grants from Pfizer and from Vifor. Further, Prof. Bischoff-Ferrari reports non-financial support from Roche Diagnostics and personal fees from Wild, Sandoz, Pfizer, Vifor, Mylan, Roche, Meda Pharma, outside the submitted work with regard to speaker fees and travel fees. J.R. Center has received honoraria for speaking at educational meetings and for advisory boards from Amgen and honoraria for an advisory board from Bayer. R. Chapurlat has no financial interest in FRAX. He has received grant funding from Amgen, UCB, Chugai, MSD, Mylan and Medac. He has received honoraria from Amgen, UCB, Chugai, Galapagos, Biocon, Abbvie, Haoma Medica, Pfizer, Amolyt, MSD, Lilly, BMS, Novartis, Arrow, PKMed, Kyowa-Kirin, and Sanofi. C. Christiansen owns stock in Nordic Bioscience. He declares no competing interests in relation to this work. C. Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda. and UCB. A. Diez-Perez reports personal fees from Amgen, Lilly, Theramex and grants from Instituto Carlos III and owns shares of Active Life Scientific, all outside the submitted work. J.A. Eisman declares consulting and research support from Actavis, Amgen, Aspen, Lilly, Merck Sharp and Dohme, Novartis, Sanofi-Aventis, Servier, and Theramex. P.J.M. Elders has no financial interest in FRAX. P.J.M. Elders reports support for the SOS study by Stichting Achmea Gezondheidszorg, Achmea, and VGZ zorgverzekeraar. Additional support was given by the stichting Artsenlaboratorium en Trombosedienst. Outside the submitted work, she did receive independent investigator-driven grants by Zonmw, the Netherlands; de Hartstichting, the Netherlands; the European foundation for the study of Diabetes, Amgen, the Netherlands; TEVA, the Netherlands; and Takeda, the Netherlands. Claus-C. Glüer reports honoraria and research support from AgNovos, Amgen, Osteolabs, and UCB unrelated to this work. N.C. Harvey has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare, and Internis Pharma. D.P. Kiel has no financial interest in FRAX but has received support for his work in the Framingham Study over the past 30 years by the National Institutes of Health, Astra Zeneca, Merck, Amgen, and Radius Health. MA Kotowicz has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia. He has served on advisory boards for Amgen Australia, Novartic, and Eli Lilly—all unrelated to this work, and is the Director of the Geelong Bone Densitometry Service. M. Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health, all outside the presented work. E.V. McCloskey has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott, and I3 Innovus. C. Ohlsson is listed as a coinventor on two patent applications regarding probiotics in osteoporosis treatment. E.S. Orwoll reports consulting fees from Amgen, Biocon, Radius, and Bayer, and research support from Mereo. J.A. Pasco has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia, all unrelated to this work. K.M.A. Swart is an employee of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. N.C. Wright sits on the Board of Trustee of the US Bone Health and Osteoporosis Foundation and has received consulting fees from Radius and ArgenX. M.C. Zillikens has received honoraria in the past for lectures or advice from Alexion, Amgen, Eli Lilly, Kyowa Kirin, Shire, and UCB, unrelated to the current work. M. Zwart has received research funding from national societies (SEMFYC and SEIOMM). C. Beaudart, E. Biver, O. Bruyère, J.A. Cauley, C.J. Crandall, S.R. Cummings, J.A.P. da Silva, B. Dawson-Huges, A.B. Dufour, S. Ferrari, Y. Fujita, S. Fujiwara, I. Goldshtein, D. Goltzman, V. Gudnason, J. Hall, D. Hans, M. Hoff, R.J. Hollick, M. Huisman, M. Iki, S. Ish-Shalom, H. Johansson, G. Jones, M.K. Karlsson, S. Khosla, W.-P. Koh, F. Koromani, H. Kröger, T. Kwok, O. Lamy, A. Langhammer, B. Larijani, W.D. Leslie, K. Lippuner, E. Liu, D. Mellström, T. Merlijn, A. Nordström, P. Nordström, T.W. O’Neill, B. Obermayer-Pietsch, F. Rivadeneira, A.-M. Schott, E.J. Shiroma, K. Sigeirsdottir, E.M. Simonsick, E. Sornay-Rendu, R. Sund, K.M.A. Swart, P. Szulc, J. Tamaki, D.J. Torgerson, L. Vandenput, N.M. van Schoor, T.P. van Staa, J. Vila, N.J. Wareham, and N. Yoshimura declare no competing interests in relation to this work.